Point-of-Care Testing for Anticoagulation Monitoring in Neuroendovascular Procedures

References

1. 1.↵
   1. Riedel CH,
   2. Tietke M,
   3. Alfke K,
   4. et al

   . Subacute stent thrombosis in intracranial stenting. Stroke 2009;40:1310–14

   Abstract/FREE Full Text
2. 2.↵
   1. Ries T,
   2. Buhk JH,
   3. Kucinski T,
   4. et al

   . Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke 2006;37:1816–21

   Abstract/FREE Full Text
3. 3.↵
   1. Qureshi AI,
   2. Luft AR,
   3. Sharma M,
   4. et al

   . Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures. Part II. Clinical aspects and recommendations. Neurosurgery 2000;46:1360–75, discussion 75–76

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Krpski WC,
   2. Bass A,
   3. Kelly AB,
   4. et al

   . Heparin-resistant thrombus formation by endovascular stents in baboons: interruption by a synthetic antithrombin. Circulation 1990;82:570–77

   Abstract/FREE Full Text
5. 5.↵
   1. Chaer RA,
   2. Graham JA,
   3. Mureebe L

   . Platelet function and pharmacologic inhibition. Vasc Endovascular Surg 2006;40:261–67

   Abstract/FREE Full Text
6. 6.↵
   1. Hirsh J,
   2. Bauer KA,
   3. Donati MB,
   4. et al

   . Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 suppl):141S–59S

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Laux V,
   2. Perzborn E,
   3. Heitmeier S,
   4. et al

   . Direct inhibitors of coagulation proteins: the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009;102:892–99

   PubMedWeb of Science
8. 8.↵
   1. SoRelle R

   . 1999 Bristol-Myers Squibb cardiovascular metabolic research award: Earl Davie, PhD, defined the system of blood coagulation. Circulation 1999;100:332

   FREE Full Text
9. 9.↵
   1. Montalescot G,
   2. White HD,
   3. Gallo R,
   4. et al

   . Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006–17

   CrossRefPubMedWeb of Science
10. 10.↵
    1. El Rouby S,
    2. Cohen M,
    3. Gonzales A,
    4. et al

    . The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures. J Thromb Thrombolysis 2006;21:137–45

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Saw J,
    2. Kereiakes DJ,
    3. Mahaffey KW,
    4. et al

    . Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res 2003;112:301–06

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Toschi V,
    2. Lettino M,
    3. Gallo R,
    4. et al

    . Biochemistry and biology of hirudin. Coron Artery Dis 1996;7:420–28

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Warkentin TE,
    2. Greinacher A,
    3. Koster A

    . Bivalirudin. Thromb Haemost 2008, 99:830–39

    PubMedWeb of Science
14. 14.↵
    1. Witting JI,
    2. Bourdon P,
    3. Maraganore JM,
    4. et al

    . Hirulog-1 and -B2 thrombin specificity. Biochem J 1992;287(pt 2):663–64

    FREE Full Text
15. 15.↵
    1. Bittl JA,
    2. Chaitman BR,
    3. Feit F,
    4. et al

    . Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952–59

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Lincoff AM,
    2. Kleiman NS,
    3. Kottke-Marchant K,
    4. et al

    . Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847–53

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Lincoff AM,
    2. Bittl JA,
    3. Harrington RA,
    4. et al

    . Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853–63

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Stone GW,
    2. McLaurin BT,
    3. Cox DA,
    4. et al

    . Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203–16

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Stone GW,
    2. Witzenbichler B,
    3. Guagliumi G,
    4. et al

    . Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218–30

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Swan SK,
    2. Hursting MJ

    . The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318–29

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Chia S,
    2. Van Cott EM,
    3. Raffel OC,
    4. et al

    . Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost 2009;101:535–40

    PubMed
22. 22.↵
    1. van Putten J,
    2. van de Ruit M,
    3. Beunis M,
    4. et al

    . Automated determination of heparin with chromogenic substrates. Haemostasis 1984;14:184–94

    PubMed
23. 23.↵
    1. Tietz NW

    , ed. Clinical guide to laboratory tests. Philadelphia: W. B. Saunders Company; 1995:228–29
24. 24.↵
    1. Hattersley PG

    . Activated coagulation time of whole blood. JAMA 1966;196:436–40

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Van Cott EM

    . Point-of-care testing in coagulation. Clin Lab Med 2009;29:543–53

    CrossRefPubMed
26. 26.↵
    1. Feindt P,
    2. Seyfert UT,
    3. Volkmer I,
    4. et al

    . Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy. Thorac Cardiovasc Surg 1994;42:218–21

    PubMedWeb of Science
27. 27.↵
    1. Andrew M,
    2. MacIntyre B,
    3. MacMillan J,
    4. et al

    . Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemost 1993;70:937–41

    PubMedWeb of Science
28. 28.↵
    1. Marmur JD,
    2. Bullock-Palmer RP,
    3. Poludasu S,
    4. et al

    . Avoiding intelligence failures in the cardiac catheterization laboratory: strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. J Invasive Cardiol 2009;21:653–64

    PubMed
29. 29.↵
    1. Lawrence M,
    2. Mixon TA,
    3. Cross D,
    4. et al

    . Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Interv 2004;61:52–55

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Marmur JD,
    2. Anand SX,
    3. Bagga RS,
    4. et al

    . The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Col Cardiol 2003;41:394–402

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Dougherty KG,
    2. Gaos CM,
    3. Bush HS,
    4. et al

    . Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260–63

    PubMedWeb of Science
32. 32.↵
    1. Zahn R,
    2. Haubelt H,
    3. Bechtloff S,
    4. et al

    . Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Herz 2003;28:445–52

    CrossRefPubMed
33. 33.↵
    American Association for Clinical Chemistry. Laboratory Medicine Practice Guidelines. 2007: www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/poct/Pages/poctpdf.aspx. Accessed December 2010
34. 34.↵
    1. Shimada YJ,
    2. Nakra NC,
    3. Fox JT,
    4. et al

    . Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention. Am J Cardiol 2010;105:629–32

    CrossRefPubMed
35. 35.↵
    1. Pesola GR,
    2. Johnson A,
    3. Pesola DA

    . Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time. Cathet Cardiovasc Diagn 1996;37:140–44

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Spinler SA,
    2. Wittkowsky AK,
    3. Nutescu EA,
    4. et al

    . Anticoagulation monitoring. Part 2. Unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother 2005;39:1275–85

    CrossRefPubMedWeb of Science
37. 37.↵
    Proceedings of the seventh ACCP conference on antithrombotic and thrombolytic therapy: Evidence-based guidelines. Chest 2004;126:172S–696S

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Ferguson JJ,
    2. Dougherty KG,
    3. Gaos CM,
    4. et al

    . Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061–65

    PubMedWeb of Science
39. 39.↵
    1. Narins CR,
    2. Hillegass WB Jr.,
    3. Nelson CL,
    4. et al

    . Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667–71

    Abstract/FREE Full Text
40. 40.↵
    1. Pinto DS,
    2. Lorenz DP,
    3. Murphy SA,
    4. et al

    . Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TAC TICS-TIMI 18 substudy). Am J Cardiol 2003;91:976–78, A4

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Montalescot G,
    2. Cohen M,
    3. Salette G,
    4. et al

    . Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J 2008;29:462–71

    Abstract/FREE Full Text
42. 42.↵
    1. Chew DP,
    2. Bhatt DL,
    3. Lincoff AM,
    4. et al

    . Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961–66

    Abstract/FREE Full Text
43. 43.↵
    1. Brener SJ,
    2. Bhatt DL,
    3. Moliterno DJ,
    4. et al

    . Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol 2003;92:1468–71

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Bertrand OF,
    2. Rodes-Cabau J,
    3. Rinfret S,
    4. et al

    . Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. Am J Cardiol 2009;104:1235–40

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Schumacher HC,
    2. Meyers PM,
    3. Higashida RT,
    4. et al

    . Reporting standards for angioplasty and stent-assisted angioplasty for intracranial atherosclerosis. Stroke 2009;40:e348–65

    Abstract/FREE Full Text
46. 46.↵
    1. Jiang WJ,
    2. Wang YJ,
    3. Du B,
    4. et al

    . Stenting of symptomatic M1 stenosis of middle cerebral artery: an initial experience of 40 patients. Stroke 2004;35:1375–80

    Abstract/FREE Full Text
47. 47.↵
    1. Henkes H,
    2. Miloslavski E,
    3. Lowens S,
    4. et al

    . Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan). Neuroradiology 2005;47:222–28

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Lylyk P,
    2. Cohen JE,
    3. Ceratto R,
    4. et al

    . Angioplasty and stent placement in intracranial atherosclerotic stenoses and dissections. AJNR Am J Neuroradiol 2002;23:430–36

    Abstract/FREE Full Text
49. 49.↵
    1. Levy EI,
    2. Boulos AS,
    3. Guterman LR

    . Stent-assisted endoluminal revascularization for the treatment of intracranial atherosclerotic disease. Neurol Res 2002;24:337–46

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Castellan L,
    2. Causin F,
    3. Danieli D,
    4. et al

    . Carotid stenting with filter protection: correlation of ACT values with angiographic and histopathologic findings. J Neuroradiol 2003;30:103–08

    PubMedWeb of Science
51. 51.↵
    1. Yokote H,
    2. Terada T,
    3. Ryujin K,
    4. et al

    . Percutaneous transluminal angioplasty for intracranial arteriosclerotic lesions. Neuroradiology 1998;40:590–96

    CrossRefPubMedWeb of Science
52. 52.↵
    1. Qureshi AI,
    2. Suri MF,
    3. Siddiqui AM,
    4. et al

    . Clinical and angiographic results of dilatation procedures for symptomatic intracranial atherosclerotic disease. J Neuroimaging 2005;15:240–49

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Gress DR,
    2. Smith WS,
    3. Dowd CF,
    4. et al

    . Angioplasty for intracranial symptomatic vertebrobasilar ischemia. Neurosurgery 2002;51:23–27, discussion 27–29

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Saw J,
    2. Bajzer C,
    3. Casserly IP,
    4. et al

    . Evaluating the optimal activated clotting time during carotid artery stenting. Am J Cardiol 2006;97:1657–60

    CrossRefPubMed
55. 55.↵
    1. Yadav JS,
    2. Wholey MH,
    3. Kuntz RE,
    4. et al

    . Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493–501

    CrossRefPubMedWeb of Science
56. 56.↵
    1. Brott TG,
    2. Hobson RW 2nd.,
    3. Howard G,
    4. et al

    . Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11–23. Epub 2010 May 26

    CrossRefPubMedWeb of Science
57. 57.↵
    1. Cavusoglu E,
    2. Lakhani M,
    3. Marmur JD

    . The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. J Invasive Cardiol 2005;17:416–21

    PubMed
58. 58.↵
    1. Marmur JD,
    2. Lakhani M,
    3. El Rouby S,
    4. et al

    . A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory. J Invasive Cardiol 2008;20:449–54

    PubMedWeb of Science
59. 59.↵
    1. Silvain J,
    2. Beygui F,
    3. Ankri A,
    4. et al

    . Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Cardiol 2010;55:617–25

    CrossRefPubMedWeb of Science
60. 60.↵
    1. Casserly IP,
    2. Topol EJ,
    3. Jia G,
    4. et al

    . Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes: observations from the TARGET trial. Am J Cardiol 2003;92:125–29

    PubMed
61. 61.↵
    1. Moliterno DJ,
    2. Califf RM,
    3. Aguirre FV,
    4. et al

    . Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559–62

    CrossRefPubMedWeb of Science
62. 62.↵
    1. Ammar T,
    2. Scudder LE,
    3. Coller BS

    . In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614–17

    Abstract/FREE Full Text
63. 63.↵
    1. Dauerman HL,
    2. Ball SA,
    3. Goldberg RJ,
    4. et al

    . Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention. J Thromb Thrombolysis. 2002;13:127–32

    CrossRefPubMed
64. 64.↵
    1. Furman MI,
    2. Krueger LA,
    3. Frelinger AL 3rd.,
    4. et al

    . GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000;84:492–98

    PubMed
65. 65.↵
    1. Smith SC Jr.,
    2. Feldman TE,
    3. Hirshfeld JW Jr.,
    4. et al

    . ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166–286

    FREE Full Text
66. 66.↵
    1. Tolleson TR,
    2. O'Shea JC,
    3. Bittl JA,
    4. et al

    . Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003;41:386–93

    CrossRefPubMedWeb of Science
67. 67.↵
    Hemochron [package insert]. http://www.itcmed.com/Products 2010
68. 68.↵
    1. Pan C-M,
    2. Jobes D,
    3. Van Riper D,
    4. et al

    . A modified microsample ACT test for heparin monitoring. J Extra Corpor Technol 1996;28:16–20
69. 69.↵
    1. Despotis GJ,
    2. Joist JH,
    3. Hogue CW Jr.,
    4. et al

    . The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46–54

    CrossRefPubMedWeb of Science
70. 70.↵
    1. Jaryno SA,
    2. Zucker ML,
    3. LaDuca FM

    . The Hemochron Response RxDx heparin and protamine dosing system. J Extra Corpor Technol 2004;36:258–62

    PubMed
71. 71.↵
    1. Shore-Lesserson L,
    2. Reich DL,
    3. DePerio M

    . Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998;45:10–18

    PubMedWeb of Science
72. 72.↵
    1. Silvain J,
    2. Beygui F,
    3. Ankri A,
    4. et al

    . Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Cardiol 2010;55:617–25

    CrossRefPubMedWeb of Science
73. 73.↵
    Medtronic; Minneapolis, Minnesota. http://www.medtronic.com/for-healthcare-professionals/products-therapies/cardiovascular/therapies/perfusion/index.htm#tab2. Accessed December 2010
74. 74.↵
    1. Despotis GJ,
    2. Alsoufiev AL,
    3. Spitznagel E,
    4. et al

    . Response of kaolin act to haparin: Evaluation with an automated assay and higher heparin doses. Annal Thoracic Surg 1996;61:795–99

    CrossRef
75. 75.↵
    1. Despotis GJ,
    2. Summerfield AL,
    3. Joist JH,
    4. et al

    . Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-xa heparin concentration in patients having cardiac operations. J Thoracic Cardiovasc Surg 1994;108:1076–82

    PubMedWeb of Science
76. 76.↵
    1. Garvin S,
    2. Fitzgerald DC,
    3. Despotis G,
    4. et al

    . Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010;111:849–55. Epub 2009 Oct 27

    CrossRefPubMedWeb of Science
77. 77.↵
    1. Gravlee G,
    2. Davis R,
    3. Stammers A,
    4. et al

    . Cardiopulmonary Bypass: Principles and Practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008
78. 78.↵
    1. Owings JT,
    2. Pollock ME,
    3. Gosselin RC,
    4. et al

    . Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. Arch Surg 2000;135:1042–47

    CrossRefPubMedWeb of Science
79. 79.↵
    1. Helft G,
    2. Bartolomeo P,
    3. Zaman AG,
    4. et al

    . The heparin management test: a new device for monitoring anticoagulation during coronary intervention. Thrombosis Res 1999;96:481–85

    CrossRefPubMed
80. 80.↵
    1. Tsimikas S,
    2. Beyer R,
    3. Hassankhani A

    . Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention. J Thromb Thrombolysis 2001;11:217–21

    CrossRefPubMed
81. 81.↵
    1. Ganter MT,
    2. Dalbert S,
    3. Graves K,
    4. et al

    . Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT. Anesth Analg 2005;101:308–14

    CrossRefPubMed
82. 82.↵
    1. Ganter MT,
    2. Monn A,
    3. Tavakoli R,
    4. et al

    . Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur J Cardiothorac Surg 2006;30:278–84

    Abstract/FREE Full Text
83. 83.↵
    1. Paniccia R,
    2. Fedi S,
    3. Carbonetto F,
    4. et al

    . Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings: the i-STAT celite-activated clotting time test. Anesthesiology 2003;99:54–59

    CrossRefPubMedWeb of Science
84. 84.↵
    1. Bosch YP,
    2. Ganushchak YM,
    3. de Jong DS

    . Comparison of ACT point-of-care measurements: repeatability and agreement. Perfusion 2006;21:27–31

    Abstract/FREE Full Text
85. 85.↵
    1. Espana F,
    2. Ratnoff OD

    . Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med 1983;102:31–45

    PubMed
86. 86.↵
    1. Leyvi G,
    2. Shore-Lesserson L,
    3. Harrington D,
    4. et al

    . An investigation of a new activated clotting time “MAX-ACT” in patients undergoing extracorporeal circulation. Anesth Analg 2001;92:578–83

    CrossRefPubMed
87. 87.
    1. Prisco D,
    2. Paniccia R

    . Point-of-care testing of hemostasis in cardiac surgery. Thromb J 2003;1:1

    CrossRefPubMed
88. 88.↵
    1. Ganter MT,
    2. Hofer CK

    . Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366–75

    CrossRefPubMedWeb of Science
89. 89.↵
    1. Wang JS,
    2. Lin CY,
    3. Hung WT,
    4. et al

    . Thromboelastogram fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 1992;53:435–39

    CrossRefPubMedWeb of Science
90. 90.↵
    1. Luddington RJ

    . Thrombelastography/thromboelastometry. Clin Lab Haematol 2005;27:81–90

    CrossRefPubMedWeb of Science